We are live on ! Find out more
CCXI

ChemoCentryx, Inc.

Delisted

CCXI was delisted on the 19th of October, 2022.

182 hedge funds and large institutions have $1.44B invested in ChemoCentryx, Inc. in 2022 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 72 increasing their positions, 52 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

292% more call options, than puts

Call options by funds: $40.3M | Put options by funds: $10.3M

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

38% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 52

30% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 30

3% more funds holding

Funds holding: 176182 (+6)

3% more capital invested

Capital invested by funds: $1.4B → $1.44B (+$40.7M)

Holders
182
Holders Change
+6
Holders Change %
+3.41%
% of All Funds
3.07%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
39
Increased
72
Reduced
52
Closed
30
Calls
$40.3M
Puts
$10.3M
Net Calls
+$30M
Net Calls Change
+$12.9M
Name Holding Trade Value Shares
Change
Change in
Stake
TLP
26
Tri Locum Partners
New York
$13.5M +$5.49M +249,205 +84%
Goldman Sachs
27
Goldman Sachs
New York
$11.8M +$2.03M +92,086 +24%
PA
28
Perceptive Advisors
New York
$10.9M -$26.7M -1,213,399 -73%
Charles Schwab
29
Charles Schwab
California
$9.47M +$321K +14,545 +4%
Millennium Management
30
Millennium Management
New York
$9.19M -$20.5M -930,257 -72%
Voloridge Investment Management
31
Voloridge Investment Management
Florida
$8.98M -$6.66M -301,944 -45%
T. Rowe Price Associates
32
T. Rowe Price Associates
Maryland
$7.68M -$1.22M -55,505 -15%
Citadel Advisors
33
Citadel Advisors
Florida
$7.54M -$42K -1,906 -0.6%
Prudential Financial
34
Prudential Financial
New Jersey
$7.18M +$6.39M +289,810 New
RJA
35
Raymond James & Associates
Florida
$7.03M -$247K -11,213 -4%
RJFSA
36
Raymond James Financial Services Advisors
Florida
$6.43M +$272K +12,347 +5%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$5.9M -$1.07M -48,670 -17%
TIM
38
Thornburg Investment Management
New Mexico
$5.47M -$564K -25,602 -10%
Bank of America
39
Bank of America
North Carolina
$5.1M -$2.11M -95,804 -32%
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$4.84M -$2.75M -124,852 -39%
LCG
41
Lisanti Capital Growth
New York
$4.58M -$3.01M -136,623 -42%
Lord, Abbett & Co
42
Lord, Abbett & Co
New Jersey
$4.47M +$3.97M +180,285 New
GIM
43
Granahan Investment Management
Massachusetts
$4.17M +$1M +45,478 +37%
ACM
44
Altium Capital Management
New York
$3.96M +$3.53M +160,000 New
Citigroup
45
Citigroup
New York
$3.95M +$2.58M +117,029 +276%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$3.88M -$1.4M -63,300 -29%
SCM
47
Soleus Capital Management
Connecticut
$3.83M +$3.4M +154,400 New
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$3.82M -$401K -18,198 -11%
Rafferty Asset Management
49
Rafferty Asset Management
New York
$3.78M -$1.61M -73,036 -32%
Assenagon Asset Management
50
Assenagon Asset Management
Luxembourg
$3.45M -$497K -22,556 -14%

CCXI Hedge Fund Activity: Q2 2022 in Review

182 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q2 2022, worth a combined $1.44B — up 2.9% from $1.4B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CCXI positions and 30 closed out — a net gain of 9 holders — while 72 added to existing stakes and 52 trimmed.

The largest buyer was Hood River Capital Management, opening a new position worth an estimated $29.5M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $29.5M sold.

  • 182 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q2 2022, up from 176 in Q1 2022.
  • Funds reported $1.44B of ChemoCentryx, Inc. stock for Q2 2022, up 2.9% quarter-over-quarter.
  • 39 funds opened new ChemoCentryx, Inc. positions in Q2 2022 and 30 closed out, a net change of +9 holders.
  • The largest ChemoCentryx, Inc. buyer in Q2 2022 was Hood River Capital Management, an estimated $29.5M added.
  • The largest ChemoCentryx, Inc. seller in Q2 2022 was Avidity Partners Management, an estimated $29.5M sold.

Based on aggregated 13F filings for Q2 2022.